{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:57:20Z","timestamp":1789520240114,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C1010354"],"award-info":[{"award-number":["NRF-2022R1A2C1010354"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017M3C7A1031108"],"award-info":[{"award-number":["NRF-2017M3C7A1031108"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-2017M3C7A1031105"],"award-info":[{"award-number":["NRF-2017M3C7A1031105"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levodopa (L-DOPA) treatment is a clinically effective strategy for improving motor function in patients with ischemic stroke. However, the mechanisms by which modulating the dopamine system relieves the pathology of the ischemic brain remain unclear. Emerging evidence from an experimental mouse model of ischemic stroke, established by middle cerebral artery occlusion (MCAO), suggested that L-DOPA has the potential to modulate the inflammatory and immune response that occurs during a stroke. Here, we aimed to demonstrate the therapeutic effect of L-DOPA in regulating the systemic immune response and improving functional deficits in mice with ischemia. Transient MCAO led to progressive degeneration of nigrostriatal dopamine neurons and significant rotational behavior in mice. Exogenous L-DOPA treatment attenuated the striatonigral degeneration and reversed motor behavioral impairment. Notably, treatment with L-DOPA significantly increased IL-13 but reduced IFN-\u03b3 in infarct lesions. To investigate the role of IL-13 in motor behavior, we stereotaxically injected anti-IL-13 antibodies into the infarct area of the mouse brain one week after MCAO, followed by L-DOPA treatment. The intervention reduced dopamine, IL-13, and IL-10 levels and exacerbated motor function. IL-13 is potentially expressed on CD4 T cells, while IL-10 is mainly expressed on microglia rather than astrocytes. Finally, IL-13 activates the phagocytosis of microglia, which may contribute to neuroprotection by eliminating degenerating neurons. Our study provides evidence that the L-DOPA-activated dopamine system modulates peripheral immune cells, resulting in the expression of anti-inflammatory and neuroprotective cytokines in mice with ischemic stroke.<\/jats:p>","DOI":"10.1038\/s41419-024-07252-x","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:29:50Z","timestamp":1732278590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuroprotective effect of L-DOPA-induced interleukin-13 on striatonigral degeneration in cerebral ischemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Eunhae","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong-Seong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkhmaa","family":"Lkhagva-Yondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ree","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-9493","authenticated-orcid":false,"given":"Byoung Dae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayul","family":"Wi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Yoon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Cheul","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Kwan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-8735","authenticated-orcid":false,"given":"Myung-Shin","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"7252_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40478-022-01327-6","volume":"10","author":"S Lohmann","year":"2022","unstructured":"Lohmann S, Grigoletto J, Bernis ME, Pesch V, Ma L, Reithofer S, et al. Ischemic stroke causes Parkinson\u2019s disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein. Acta Neuropathol Commun. 2022;10:26.","journal-title":"Acta Neuropathol Commun"},{"key":"7252_CR2","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1523\/JNEUROSCI.0195-15.2015","volume":"35","author":"HS Xenias","year":"2015","unstructured":"Xenias HS, Ibanez-Sandoval O, Koos T, Tepper JM. Are striatal tyrosine hydroxylase interneurons dopaminergic? J Neurosci. 2015;35:6584\u201399.","journal-title":"J Neurosci"},{"key":"7252_CR3","doi-asserted-by":"crossref","unstructured":"Mallet N, Delgado L, Chazalon M, Miguelez C, Baufreton J. Cellular and synaptic dysfunctions in Parkinson\u2019s disease: stepping out of the striatum. Cells. 2019;8:1005.","DOI":"10.3390\/cells8091005"},{"key":"7252_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0091-3057(95)00108-9","volume":"52","author":"CV Borlongan","year":"1995","unstructured":"Borlongan CV, Martinez R, Shytle RD, Freeman TB, Cahill DW, Sanberg PR. Striatal dopamine-mediated motor behavior is altered following occlusion of the middle cerebral artery. Pharm Biochem Behav. 1995;52:225\u20139.","journal-title":"Pharm Biochem Behav"},{"key":"7252_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/01.STR.23.3.328","volume":"23","author":"M Nakane","year":"1992","unstructured":"Nakane M, Teraoka A, Asato R, Tamura A. Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke. 1992;23:328\u201332.","journal-title":"Stroke"},{"key":"7252_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5853\/jos.2022.02145","volume":"25","author":"K Lee","year":"2023","unstructured":"Lee K, Lee H, Kim YD, Nam HS, Lee HS, Yoo J, et al. Association of substantia Nigra degeneration with poor neurological recovery in Basal Ganglia infarctions. J Stroke. 2023;25:169\u201372.","journal-title":"J Stroke"},{"key":"7252_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1161\/STROKEAHA.122.038701","volume":"53","author":"KW Park","year":"2022","unstructured":"Park KW, Ju H, Kim ID, Cave JW, Guo Y, Wang W, et al. Delayed infiltration of peripheral monocyte contributes to phagocytosis and transneuronal degeneration in chronic stroke. Stroke. 2022;53:2377\u201388.","journal-title":"Stroke"},{"key":"7252_CR8","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/STROKEAHA.111.632448","volume":"43","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhang Y, Xing S, Liang Z, Zeng J. Secondary neurodegeneration in remote regions after focal cerebral infarction: a new target for stroke management? Stroke. 2012;43:1700\u20135.","journal-title":"Stroke"},{"key":"7252_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.baga.2016.02.001","volume":"6","author":"D Sulzer","year":"2016","unstructured":"Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia. 2016;6:123\u201348.","journal-title":"Basal Ganglia"},{"key":"7252_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ibneur.2022.05.008","volume":"13","author":"C Vitrac","year":"2022","unstructured":"Vitrac C, Nallet-Khosrofian L, Iijima M, Rioult-Pedotti MS, Luft A. Endogenous dopamine transmission is crucial for motor skill recovery after stroke. IBRO Neurosci Rep. 2022;13:15\u201321.","journal-title":"IBRO Neurosci Rep"},{"key":"7252_CR11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"PA Lewitt","year":"2008","unstructured":"Lewitt PA. Levodopa for the treatment of Parkinson\u2019s disease. N. Engl J Med. 2008;359:2468\u201376.","journal-title":"N. Engl J Med"},{"key":"7252_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/WNF.0b013e3180ed449f","volume":"31","author":"D Nyholm","year":"2008","unstructured":"Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa\/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol. 2008;31:63\u201373.","journal-title":"Clin Neuropharmacol"},{"key":"7252_CR13","first-page":"277","volume":"27","author":"M Acler","year":"2009","unstructured":"Acler M, Fiaschi A, Manganotti P. Long-term levodopa administration in chronic stroke patients. A clinical and neurophysiologic single-blind placebo-controlled cross-over pilot study. Restor Neurol Neurosci. 2009;27:277\u201383.","journal-title":"Restor Neurol Neurosci"},{"key":"7252_CR14","doi-asserted-by":"crossref","unstructured":"Fahn S. Levodopa in the treatment of Parkinson\u2019s disease. J Neural Transm Suppl. 2006;(71):1\u201315.","DOI":"10.1007\/978-3-211-33328-0_1"},{"key":"7252_CR15","first-page":"229","volume":"5","author":"W Poewe","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clin Inter Aging. 2010;5:229\u201338.","journal-title":"Clin Inter Aging"},{"key":"7252_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD-130186","volume":"3","author":"D Salat","year":"2013","unstructured":"Salat D, Tolosa E. Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments. J Parkinsons Dis. 2013;3:255\u201369.","journal-title":"J Parkinsons Dis"},{"key":"7252_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0140-6736(01)05966-9","volume":"358","author":"K Scheidtmann","year":"2001","unstructured":"Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001;358:787\u201390.","journal-title":"Lancet"},{"key":"7252_CR18","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1007\/s00415-010-5732-z","volume":"257","author":"M Zappia","year":"2010","unstructured":"Zappia M, Colosimo C, Poewe W. Levodopa: back to the future. J Neurol. 2010;257:S247\u201348.","journal-title":"J Neurol"},{"key":"7252_CR19","volume":"14","author":"JA Moncayo","year":"2022","unstructured":"Moncayo JA, Yepez M, Camacho M, Aguirre AS, Ojeda D, Ortiz JF, et al. Use of levodopa after a stroke: a systematic review. Cureus. 2022;14:e24529.","journal-title":"Cureus"},{"key":"7252_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577328","volume":"347","author":"R Espinosa-Cardenas","year":"2020","unstructured":"Espinosa-Cardenas R, Arce-Sillas A, Alvarez-Luquin D, Leyva-Hernandez J, Montes-Moratilla E, Gonzalez-Saavedra I, et al. Immunomodulatory effect and clinical outcome in Parkinson\u2019s disease patients on levodopa-pramipexole combo therapy: a two-year prospective study. J Neuroimmunol. 2020;347:577328.","journal-title":"J Neuroimmunol"},{"key":"7252_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105700","volume":"168","author":"F Weiss","year":"2022","unstructured":"Weiss F, Labrador-Garrido A, Dzamko N, Halliday G. Immune responses in the Parkinson\u2019s disease brain. Neurobiol Dis. 2022;168:105700.","journal-title":"Neurobiol Dis"},{"key":"7252_CR22","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s13311-019-00761-0","volume":"16","author":"N Kolosowska","year":"2019","unstructured":"Kolosowska N, Keuters MH, Wojciechowski S, Keksa-Goldsteine V, Laine M, Malm T, et al. Peripheral administration of IL-13 induces anti-inflammatory microglial\/macrophage responses and provides neuroprotection in ischemic stroke. Neurotherapeutics. 2019;16:1304\u201319.","journal-title":"Neurotherapeutics"},{"key":"7252_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02471-5","volume":"19","author":"D Chen","year":"2022","unstructured":"Chen D, Li J, Huang Y, Wei P, Miao W, Yang Y, et al. Interleukin 13 promotes long-term recovery after ischemic stroke by inhibiting the activation of STAT3. J Neuroinflammation. 2022;19:112.","journal-title":"J Neuroinflammation"},{"key":"7252_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4049\/jimmunol.177.2.1323","volume":"177","author":"MS Yang","year":"2006","unstructured":"Yang MS, Ji KA, Jeon SB, Jin BK, Kim SU, Jou I, et al. Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J Immunol. 2006;177:1323\u20139.","journal-title":"J Immunol"},{"key":"7252_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/glia.10057","volume":"38","author":"MS Yang","year":"2002","unstructured":"Yang MS, Park EJ, Sohn S, Kwon HJ, Shin WH, Pyo HK, et al. Interleukin-13 and -4 induce death of activated microglia. Glia. 2002;38:273\u201380.","journal-title":"Glia"},{"key":"7252_CR26","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.immuni.2019.10.002","volume":"51","author":"W Wang","year":"2019","unstructured":"Wang W, Cohen JA, Wallrapp A, Trieu KG, Barrios J, Shao F, et al. Age-related dopaminergic innervation augments T helper 2-type allergic inflammation in the postnatal lung. Immunity. 2019;51:1102\u201318.e1107.","journal-title":"Immunity"},{"key":"7252_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.immuni.2022.12.017","volume":"56","author":"Y Cao","year":"2023","unstructured":"Cao Y, Li Y, Wang X, Liu S, Zhang Y, Liu G, et al. Dopamine inhibits group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity. Immunity. 2023;56:320\u201335.e329.","journal-title":"Immunity"},{"key":"7252_CR28","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1523\/JNEUROSCI.2890-15.2015","volume":"35","author":"E Kim","year":"2015","unstructured":"Kim E, Woo MS, Qin L, Ma T, Beltran CD, Bao Y, et al. Daidzein augments cholesterol homeostasis via ApoE to promote functional recovery in chronic stroke. J Neurosci. 2015;35:15113\u201326.","journal-title":"J Neurosci"},{"key":"7252_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5607\/en20062","volume":"30","author":"M Kim","year":"2021","unstructured":"Kim M, Kim SD, Kim KI, Jeon EH, Kim MG, Lim YR, et al. Dynamics of T lymphocyte between the periphery and the brain from the acute to the chronic phase following ischemic stroke in mice. Exp Neurobiol. 2021;30:155\u201369.","journal-title":"Exp Neurobiol"},{"key":"7252_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/nbdi.1995.0001","volume":"2","author":"BK Jin","year":"1995","unstructured":"Jin BK, Iacovitti L. Dopamine differentiation factors produce partial motor recovery in 6-hydroxydopamine lesioned rats. Neurobiol Dis. 1995;2:1\u201312.","journal-title":"Neurobiol Dis"},{"key":"7252_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fnagi.2018.00237","volume":"10","author":"P Perez-Pardo","year":"2018","unstructured":"Perez-Pardo P, Broersen LM, Kliest T, van Wijk N, Attali A, Garssen J, et al. Additive effects of levodopa and a neurorestorative diet in a mouse model of Parkinson\u2019s disease. Front Aging Neurosci. 2018;10:237.","journal-title":"Front Aging Neurosci"},{"key":"7252_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1161\/STROKEAHA.111.638767","volume":"43","author":"K Ruscher","year":"2012","unstructured":"Ruscher K, Kuric E, Wieloch T. Levodopa treatment improves functional recovery after experimental stroke. Stroke. 2012;43:507\u201313.","journal-title":"Stroke"},{"key":"7252_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jneuroim.2014.02.009","volume":"269","author":"E Kuric","year":"2014","unstructured":"Kuric E, Ruscher K. Reversal of stroke induced lymphocytopenia by levodopa\/benserazide treatment. J Neuroimmunol. 2014;269:94\u201397.","journal-title":"J Neuroimmunol"},{"key":"7252_CR34","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1111\/ejn.12598","volume":"40","author":"E Kuric","year":"2014","unstructured":"Kuric E, Ruscher K. Reduction of rat brain CD8+ T-cells by levodopa\/benserazide treatment after experimental stroke. Eur J Neurosci. 2014;40:2463\u201370.","journal-title":"Eur J Neurosci"},{"key":"7252_CR35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.immuni.2018.07.015","volume":"49","author":"JD Proto","year":"2018","unstructured":"Proto JD, Doran AC, Gusarova G, Yurdagul A Jr, Sozen E, Subramanian M, et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity. 2018;49:666\u201377.e666.","journal-title":"Immunity"},{"key":"7252_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fncir.2014.00055","volume":"8","author":"SA Sharples","year":"2014","unstructured":"Sharples SA, Koblinger K, Humphreys JM, Whelan PJ. Dopamine: a parallel pathway for the modulation of spinal locomotor networks. Front Neural Circuits. 2014;8:55.","journal-title":"Front Neural Circuits"},{"key":"7252_CR37","doi-asserted-by":"crossref","unstructured":"Nakmode DD, Day CM, Song Y, Garg S. The management of Parkinson\u2019s disease: an overview of the current advancements in drug delivery systems. Pharmaceutics. 2023;15:1503.","DOI":"10.3390\/pharmaceutics15051503"},{"key":"7252_CR38","doi-asserted-by":"crossref","unstructured":"Mori S, Maher P, Conti B. Neuroimmunology of the interleukins 13 and 4. Brain Sci. 2016;6:18.","DOI":"10.3390\/brainsci6020018"},{"key":"7252_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0862-1","volume":"14","author":"S Mori","year":"2017","unstructured":"Mori S, Sugama S, Nguyen W, Michel T, Sanna MG, Sanchez-Alavez M, et al. Lack of interleukin-13 receptor alpha1 delays the loss of dopaminergic neurons during chronic stress. J Neuroinflammation. 2017;14:88.","journal-title":"J Neuroinflammation"},{"key":"7252_CR40","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.4049\/jimmunol.1102150","volume":"189","author":"BE Morrison","year":"2012","unstructured":"Morrison BE, Marcondes MC, Nomura DK, Sanchez-Alavez M, Sanchez-Gonzalez A, Saar I, et al. Cutting edge: IL-13Ralpha1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol. 2012;189:5498\u2013502.","journal-title":"J Immunol"},{"key":"7252_CR41","doi-asserted-by":"crossref","unstructured":"Jeong JY, Wi R, Chung YC, Jin BK. Interleukin-13 propagates prothrombin kringle-2-induced neurotoxicity in hippocampi in vivo via oxidative stress. Int J Mol Sci. 2021;22:3486.","DOI":"10.3390\/ijms22073486"},{"key":"7252_CR42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1089\/ars.2011.4175","volume":"16","author":"JH Nam","year":"2012","unstructured":"Nam JH, Park KW, Park ES, Lee YB, Lee HG, Baik HH, et al. Interleukin-13\/-4-induced oxidative stress contributes to death of hippocampal neurons in abeta1-42-treated hippocampus in vivo. Antioxid Redox Signal. 2012;16:1369\u201383.","journal-title":"Antioxid Redox Signal"},{"key":"7252_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cyto.2017.09.018","volume":"103","author":"P Maher","year":"2018","unstructured":"Maher P, Conti B. Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death. Cytokine. 2018;103:114\u201320.","journal-title":"Cytokine"},{"key":"7252_CR44","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.4049\/jimmunol.1900909","volume":"204","author":"W Miao","year":"2020","unstructured":"Miao W, Zhao Y, Huang Y, Chen D, Luo C, Su W, et al. IL-13 ameliorates neuroinflammation and promotes functional recovery after traumatic brain injury. J Immunol. 2020;204:1486\u201398.","journal-title":"J Immunol"},{"key":"7252_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35806-8","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Olde Heuvel F, Rehman R, Aousji O, Froehlich A, Li Z, et al. Interleukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection. Nat Commun. 2023;14:200.","journal-title":"Nat Commun"},{"key":"7252_CR46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-018-0824-5","volume":"565","author":"M Ito","year":"2019","unstructured":"Ito M, Komai K, Mise-Omata S, Iizuka-Koga M, Noguchi Y, Kondo T, et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature. 2019;565:246\u201350.","journal-title":"Nature"},{"key":"7252_CR47","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1161\/STROKEAHA.112.659656","volume":"43","author":"X Hu","year":"2012","unstructured":"Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, et al. Microglia\/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43:3063\u201370.","journal-title":"Stroke"},{"key":"7252_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790201","volume":"12","author":"J Jia","year":"2021","unstructured":"Jia J, Yang L, Chen Y, Zheng L, Chen Y, Xu Y, et al. The role of microglial phagocytosis in ischemic stroke. Front Immunol. 2021;12:790201.","journal-title":"Front Immunol"},{"key":"7252_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","volume":"210","author":"A Michelucci","year":"2009","unstructured":"Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009;210:3\u201312.","journal-title":"J Neuroimmunol"},{"key":"7252_CR50","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.4049\/jimmunol.1203121","volume":"190","author":"H Gonzalez","year":"2013","unstructured":"Gonzalez H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson\u2019s disease. J Immunol. 2013;190:5048\u201356.","journal-title":"J Immunol"},{"key":"7252_CR51","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1096\/fj.04-1652fje","volume":"18","author":"T Ilani","year":"2004","unstructured":"Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 2004;18:1600\u20132.","journal-title":"FASEB J"},{"key":"7252_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1365-2567.1996.d01-653.x","volume":"88","author":"E Josefsson","year":"1996","unstructured":"Josefsson E, Bergquist J, Ekman R, Tarkowski A. Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology. 1996;88:140\u20136.","journal-title":"Immunology"},{"key":"7252_CR53","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/apha.12476","volume":"216","author":"M Levite","year":"2016","unstructured":"Levite M. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. 2016;216:42\u201389.","journal-title":"Acta Physiol"},{"key":"7252_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418774225","volume":"11","author":"D Talhada","year":"2018","unstructured":"Talhada D, Rabenstein M, Ruscher K. The role of dopaminergic immune cell signalling in poststroke inflammation. Ther Adv Neurol Disord. 2018;11:1756286418774225.","journal-title":"Ther Adv Neurol Disord"},{"key":"7252_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3160486","volume":"2016","author":"R Arreola","year":"2016","unstructured":"Arreola R, Alvarez-Herrera S, Perez-Sanchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez EO, et al. Immunomodulatory effects mediated by dopamine. J Immunol Res. 2016;2016:3160486.","journal-title":"J Immunol Res"},{"key":"7252_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2009.07.018","volume":"216","author":"R Pacheco","year":"2009","unstructured":"Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol. 2009;216:8\u201319.","journal-title":"J Neuroimmunol"},{"key":"7252_CR57","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.apmr.2008.02.030","volume":"89","author":"N Rosser","year":"2008","unstructured":"Rosser N, Heuschmann P, Wersching H, Breitenstein C, Knecht S, Floel A. Levodopa improves procedural motor learning in chronic stroke patients. Arch Phys Med Rehabil. 2008;89:1633\u201341.","journal-title":"Arch Phys Med Rehabil"},{"key":"7252_CR58","first-page":"243","volume":"49","author":"M Acler","year":"2013","unstructured":"Acler M, Manganotti P. Role, indications and controversies of levodopa administration in chronic stroke patients. Eur J Phys Rehabil Med. 2013;49:243\u20139.","journal-title":"Eur J Phys Rehabil Med"},{"key":"7252_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1600-0404.2010.01395.x","volume":"123","author":"J Lokk","year":"2011","unstructured":"Lokk J, Salman Roghani R, Delbari A. Effect of methylphenidate and\/or levodopa coupled with physiotherapy on functional and motor recovery after stroke-a randomized, double-blind, placebo-controlled trial. Acta Neurol Scand. 2011;123:266\u201373.","journal-title":"Acta Neurol Scand"},{"key":"7252_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-0404.2006.00728.x","volume":"115","author":"L Sonde","year":"2007","unstructured":"Sonde L, Lokk J. Effects of amphetamine and\/or L-dopa and physiotherapy after stroke\u2014a blinded randomized study. Acta Neurol Scand. 2007;115:55\u201359.","journal-title":"Acta Neurol Scand"},{"key":"7252_CR61","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","volume":"16","author":"M Lundblad","year":"2004","unstructured":"Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004;16:110\u201323.","journal-title":"Neurobiol Dis"},{"key":"7252_CR62","doi-asserted-by":"publisher","unstructured":"Cenci MA, Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson\u2019s disease in rats and mice. Curr Protoc Neurosci. 2007:9. https:\/\/doi.org\/10.1002\/0471142301.ns0925s41.","DOI":"10.1002\/0471142301.ns0925s41"},{"key":"7252_CR63","volume":"2012","author":"J Guridi","year":"2012","unstructured":"Guridi J, Gonzalez-Redondo R, Obeso JA. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. Parkinsons Dis. 2012;2012:943159.","journal-title":"Parkinsons Dis"},{"key":"7252_CR64","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1093\/brain\/awv297","volume":"138","author":"JH Nam","year":"2015","unstructured":"Nam JH, Park ES, Won SY, Lee YA, Kim KI, Jeong JY, et al. TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson\u2019s disease via CNTF. Brain. 2015;138:3610\u201322.","journal-title":"Brain"},{"key":"7252_CR65","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5093493","volume":"2020","author":"R Wi","year":"2020","unstructured":"Wi R, Chung YC, Jin BK. Functional Crosstalk between CB and TRPV1 receptors protects nigrostriatal dopaminergic neurons in the MPTP model of Parkinson\u2019s disease. J Immunol Res. 2020;2020:5093493.","journal-title":"J Immunol Res"},{"key":"7252_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.159","volume":"49","author":"YC Chung","year":"2017","unstructured":"Chung YC, Baek JY, Kim SR, Ko HW, Bok E, Shin WH, et al. Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson\u2019s disease. Exp Mol Med. 2017;49:e298.","journal-title":"Exp Mol Med"},{"key":"7252_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/srep14418","volume":"5","author":"SK Min","year":"2015","unstructured":"Min SK, Park JS, Luo L, Kwon YS, Lee HC, Shim HJ, et al. Assessment of C-phycocyanin effect on astrocytes-mediated neuroprotection against oxidative brain injury using 2D and 3D astrocyte tissue model. Sci Rep. 2015;5:14418.","journal-title":"Sci Rep"},{"key":"7252_CR68","doi-asserted-by":"publisher","unstructured":"Gaven F, Marin P, Claeysen S. Primary culture of mouse dopaminergic neurons. J Vis Exp. 2014;(91):51751. https:\/\/doi.org\/10.3791\/51751.","DOI":"10.3791\/51751"},{"key":"7252_CR69","doi-asserted-by":"publisher","unstructured":"Pruszak J, Just L, Isacson O, Nikkhah G. Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol. 2009:2. https:\/\/doi.org\/10.1002\/9780470151808.sc02d05s11.","DOI":"10.1002\/9780470151808.sc02d05s11"},{"key":"7252_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neulet.2016.09.032","volume":"633","author":"HS Jung","year":"2016","unstructured":"Jung HS, Jeong SY, Yang J, Kim SD, Zhang B, Yoo HS, et al. Neuroprotective effect of mesenchymal stem cell through complement component 3 downregulation after transient focal cerebral ischemia in mice. Neurosci Lett. 2016;633:227\u201334.","journal-title":"Neurosci Lett"},{"key":"7252_CR71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1124\/mol.110.067520","volume":"79","author":"SW Kim","year":"2011","unstructured":"Kim SW, Kim HJ, Shin JH, Kim ID, Lee JE, Han PL, et al. Robust protective effects of a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid (a salicylic acid\/pyruvate ester) in the postischemic brain. Mol Pharm. 2011;79:220\u20138.","journal-title":"Mol Pharm"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T14:06:11Z","timestamp":1732284371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-07252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["7252"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-07252-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All studies were conducted following the guidelines of the Institutional Animal Care and Use Committee of Inha University in Incheon (INHA170908-513-5; INHA180420-558-4; INHA200518-701-7; INHA230525-875-2; INHA240723-939).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"854"}}